Abstract: Coagulation factor VⅡ (FVⅡ) is a bypassing agent widely used in the treatment of bleeding in hemophilia patients with inhibitors. Novo Nordisk's NovoSeven is still the only commercially available recombinant activated FVⅡ (rFVⅡa) product in the world. However, its halflife is short and multiple injections are needed, which limits its application in the prevention and treatment of hemophilia. In this review, the longacting rFVⅡa products that are urgently under development were summarized, including those developed through PEG modification, sequence mutation and fusion protein technology. Their respective mechanisms and development progress were described, so as to provide reference for the development of long-acting rFVⅡa protein.